Background
==========

Colorectal cancer is a common malignant disease, accounting for approximately 15% of all human cancers \[[@B1]\]. In Korea, it is the third most common cancer and the fourth cause of cancer death and its incidence is increasing \[[@B2]\]. Incidence of colorectal cancer has grown rapidly since 1990, and is influenced by eating and lifestyle habits that include increased meat intake and reduced fiber intake, alcohol consumption, and smoking. Current diagnostic techniques and universal colonoscopy have enabled relatively early diagnosis of colorectal cancer, and the cure rate for early stage colorectal cancer is high, at up to 80-90% \[[@B3]\]. Although AJCC TNM classification is useful for staging of colorectal cancer patients and selection for specific treatment, it is not sufficient, as outcome may vary in different patients at the same stage, indicating that conventional staging procedures may not provide accurate prediction of cancer prognosis. Independent of the TNM Stage, the carcinoembryonic antigen (CEA) is used for prediction of prognosis; however, diagnostic sensitivity of CEA is unsatisfactory. Therefore, an appropriate molecular marker is a necessity for adequate treatment of aggressive CRC patients with adjuvant systemic chemotherapy or targeted therapy.

Because new blood vessel formation provides a route for spread of tumor cells to distant organs, angiogenesis as a central process in progression of solid tumors is a well-established aspect of cancer biology \[[@B4]\]. The process may result from an imbalance between positive and negative angiogenic regulators released by both tumor cells and host cells \[[@B5]\]. Tumor angiogenesis and its promoting growth factors have been associated with advanced stage, lymph node involvement and poor survival in a variety of human cancers \[[@B6]-[@B8]\]. One of the major pathways associated with this process is that of the vascular endothelial growth factor (VEGF) family of proteins and receptors. Indeed, many tumor cell lines secrete VEGF in vitro, and high VEGF mRNA levels can be detected by in situ hybridization in most human tumors, including lung, breast, and gastrointestinal carcinoma \[[@B9]\]. Both VEFG and its receptor are expressed at high levels in metastatic human colon carcinomas and in tumor associated endothelial cells, and production of these two proteins correlates directly with degree of tumor vascularization \[[@B10]\].

Interleukin-6 (IL-6) is a multipoietic cytokine produced by many cell types. IL-6 acts on a wide range of tissues and cell lines, and induces cell growth and differentiation, production and expression of other cytokines, and acute-phase protein synthesis. IL-6 also promotes growth arrest \[[@B11],[@B12]\], and promotes angiogenesis through induction of VEGF expression \[[@B13],[@B14]\].

C-reactive protein (CRP) is an acute reactant protein that is increased under conditions of infection, trauma, tissue necrosis, tumor, and several types of inflammatory disease. It reflects inflammatory status and is a component of the inflammatory response of the immune system \[[@B15],[@B16]\]. Several studies have reported that in occurrence, progression, metastasis, and recurrence of colorectal cancer, systemic inflammation has an important role, and that CRP may be a useful indicator of inflammatory response. Results from various studies have proven that precancerous lesions are derived from systemic inflammation and local inflammation of the mucous membrane as part of the process of cell degeneration, and that colorectal cancer progresses from adenoma to adenocarcinoma \[[@B17],[@B18]\].

Therefore, the objective of the current investigation is to assess the prognostic significance of preoperative serum VEGF, IL-6, and CRP levels as indicators of outcome in patients with colorectal cancer.

Methods
=======

Patients
--------

A total of 143 patients who underwent surgery for colorectal cancer at Dong-A University Hospital between December 2005 and December 2008 were enrolled in this study. All patients had histologically confirmed adenocarcinoma of the colon or rectum, and a 132 of the 143 had undergone a potentially curative resection. A 11 of the 143 patients showed microscopic evidence of residual disease; therefore, they were excluded. The control group consisted of 50 persons who underwent health check-ups (25 men and 25 women; median age, 41.5 years; range, 18 to 68 years) absence of neoplastic disease was established in these patients through laboratory testing including serum VEGF, IL-6 and CRP levels. Staging was based on routine postoperative histopathological analysis and clinical assessment by the American Joint Committee on Cancer (AJCC) TNM staging system. Disease status of patients was evaluated by abdominal computed tomography after surgery. CT was checked every 3 months for the first 2 years, and then every 6 months for a total of 5 years. Colonoscopy was performed at 1 year after the resection. Clinical outcomes were followed from the date of surgery to either the date of death or July 2009. A total of 11 colorectal cancer patients died of malignancy and 6 patients were lost during the observation period. The median follow-up period was 18.53 months (range 0.73-43.17). The study was approved by the Institutional Review Board (IRB). All patients provided informed consent, and the hospital review board approved the study.

Assay of serum VEGF, IL-6, and CRP
----------------------------------

Venous blood sampling was conducted within a period of 7 days prior to surgery. Blood collected for VEGF and IL-6 serum level assessments was collected in plain tubes, and levels of serum VEGF and IL-6 were measured using commercially available enzyme-linked immunosorbent assays (ELISAs). Blood samples were centrifuged for 10 min at 3,000 r/min at -4°C. Serum was subsequently removed and stored at -80°C for use in biochemical analysis. Blood samples for CRP analysis were collected in serum separation tubes, and serum CRP levels were measured via immunoturbidimetry.

Statistical analysis
--------------------

Relationships and interactions of the prognostic factors were tested using the Mann-Whitney U-test and the Kruskal Wallis test. Serum levels of VEGF, IL-6, and CRP were expressed as means and median values. VEGF, IL-6, and CRP cut-off values for survival analysis were determined by ROC curve; 825 pg/mL, 11.68 pg/mL, and 0.185 mg/dL, respectively. Duration of recurrence of colorectal cancer and death measured from the date of surgery was referenced against disease free survival and overall survival time. Survival duration was calculated via the Kaplan-Meier method. The log-rank test was employed for comparison of cumulative survival rate and disease free survival in the patient group. For identification of independent factors significantly associated with patient prognosis, we used multivariate analyses employing the Cox proportional hazards model. A *p*value \< 0.05 was considered statistically significant. Variables found to be significant at a level of *p*\< 0.05 were considered eligible for multivatiate regression analysis. The Statistical Package for Social Sciences (SPSS) Version 14.0 (SPSS Inc, Chicago, IL, USA) for Windows was utilized for all statistical analyses.

Results
=======

Patients were classified according to their pathologic characteristics, included tumor size, depth of tumor invasion, status of lymph node (LN) metastasis, lymph node ratio, CEA, American Joint Committee on Cancer tumor-nodes-metastases (AJCC TNM) stage, sex, and age. Patients included 79 men and 53 women, with a median age of 62 years (range, 26-83 years). Characteristic data for the study population are shown in Table [1](#T1){ref-type="table"}. Median follow-up duration was 19.25 months (range 0.73-43.17 months).

###### 

Patient characteristics

                             No. of patients   \%
  -------------------------- ----------------- ------
  Total number of patients   132               
  Sex                                          
   Male                      79                59.8
   Female                    53                40.2
  Median age(range)          62(26-83)         
   \<60                      52                39
   ≥60                       80                61
  CEA                                          
   ≤5 ng/mL                  99                75.6
   \>5 ng/mL                 32                24.4
  Tumor size                                   
   \<5 cm                    58                43.9
   ≥5 cm                     74                56.1
  Lymph node ratio                             
   pNr1 0.01-0.11            103               78
   pNr2 0.12-0.24            17                12.9
   pNr3 0.25-0.92            12                9.1
  Primary Tumor                                
   pT1                       12                9.1
   pT2                       19                14.4
   pT3                       90                68.2
   pT4                       11                8.3
  Regional Lymph nodes                         
   N0                        75                56.8
   N1                        36                27.3
   N2                        21                15.9
  Differentiation                              
   Well                      67                50.8
   Moderate                  52                39.4
   Poor                      5                 3.8
   Mucinous                  8                 6.1
  TNM stage                                    
   Stage I                   27                20.5
   StageII                   48                36.4
   StageIII                  57                43.2

CEA: carcinoembryonic antigen, normal range 0-5 ng/mL

Mean and median levels of VEGF and CRP in the colorectal cancer group were significantly higher than in the normal control group; 620 vs. 334 pg/mL and 541 vs. 312 pg/mL (*p*\< 0.001); 1.12 vs. 0.43 mg/dL and 0.25 vs. 0.07 mg/dL (*p*= 0.001). However mean and median level of IL-6 in patients were not significantly higher than in the control group; 13.77 vs. 5.65 pg/mL and 5.74 vs. 5.30 pg/mL (*p*= 0.437), respectively (Table [2](#T2){ref-type="table"}).

###### 

The mean and median levels of VEGF, IL-6 and CRP in colorectal cancer patients and control group

         Patients (n = 132)   Control (n = 50)     P-value                       
  ------ -------------------- -------------------- --------- ------------------- ----------
  VEGF   608                  528 (122-3242)       334       312 (16-1121)       \< 0.001
  IL-6   14.33                6.00 (1.02-139.17)   5.65      5.30 (4.50-13.78)   0.327
  CRP    1.05                 0.22 (0.00-18.40)    0.43      0.07 (0.02-6.94)    0.002

\*\* Range of Values (Serum); **VEGF**62-707 pg/mL; **IL-6**3.12-15.5 pg/mL; **CRP**0-0.5 mg/dL

Relationships between VEGF, IL-6, and CRP levels, and clinicopathologic variables were tested using the Mann-Whitney U-test and the Kruskal test. Details of these relations are listed in Table [3](#T3){ref-type="table"}. VEGF was found to be significantly correlated with tumor size (*p*= 0.012) and CEA (*p*= 0.038). But no significantly correlations were observed between VEGF and other variables. IL-6 and CRP levels were not correlated with other pathological findings.

###### 

Correlation between the IL-6, VEGF, CRP, and clinicopathological parameters

                         VEGF pg/ml   IL-6 pg/ml           CRP mg/dL                                                                              
  ---------------------- ------------ -------------------- ----------- ---------- --------------------- --------- ---------- -------------------- ---------
                         **Mean**     **Median (range)**   ***p***     **Mean**   **Median (range)**    ***p***   **Mean**   **Median (range)**   ***p***
                                                                                                                                                  
  Sex                                                                                                                                             
   Male                  656          567 (131-3242)       0048        13.12      5.03 (1.02-139.17)    0.019     1.24       0.25 (0.01-18.40)    0.827
   Female                567          469 (123-2001)                   16.14      7.71 (1.25-90.06)               0.83       0.16 (0.00-8.41)     
                                                                                                                                                  
  Age                                                                                                                                             
   \< 60                 634          569 (123-1620)       0.363       15.31      5.61 (1.02-90.06)     0.854     1.15       0.17 (0.02-8.41)     0.610
   ≥ 60                  593          494 (131-3242)                   13.70      6.63 (1.58-139.17)              0.98       0.24 (0.00-18.40)    
                                                                                                                                                  
  CEA                                                                                                                                             
   ≤ 5                   583          493 (123-32.42)      0.038       12.98      5.70 (1.02-94.11)     0.255     1.14       0.20 (0.01-18.40)    0.824
   \> 5                  680          635 (131-1619)                   18.91      8.0 (1.58-139.17)               0.80       0.25 (0.02-6.97)     
                                                                                                                                                  
  Primary tumor                                                                                                                                   
   pT1                   452          422 (123-892)        0.540       18.60      3.93 (2.18-94.11)     0.549     1.02       0.16 (0.01-6.22)     0.905
   pT2                   565          471 (139-1585)                   14.78      7.74 (1.02-70.96)               0.67       0.33 (0.02-3.43)     
   pT3                   639          546 (126-3242)                   13.35      6.02 (1.25-139.17)              1.17       0.24 (0.00-18.40)    
   pT4                   606          567 (174-1216)                   17.00      6.05 (3.44-88.96)               0.77       0.53 (0.03-2.29)     
                                                                                                                                                  
  Regional Lymph nodes                                                                                                                            
   N0                    652          539 (123-3242)       0.557       13.32      6.49 (1.02-94.11)     0.533     1.04       0.26 (0.01-10.09)    0.432
   N1                    579          562 (139-1098)                   8.53       5.66 (1.49-30.02)               1.23       0.13 (0.00-18.40     
   N2                    560          432 (156-1620)                   27.92      6.31 (1.25-139.17)              0.79       0.20 (0.02-7.83)     
                                                                                                                                                  
  Lymph node ratio                                                                                                                                
                                                                                                                                                  
   pNr1 0.01-0.11        634          558 (123-3242)       0.215       11.89      5.58 (1.02-94.11)     0.242     1.16       0.25 (0.0-18.40)     0.352
   pNr2 0.12-0.24        495          495 (145-1619)                   20.86      6.31 (1.91-90.06)               0.76       0.11 (0.00-6.97)     
   pNr3 0.25-0.92        446          430 (156-1068)                   26.10      10.15 (1.25-139.17)             0.54       0.17 (0.04-2.18)     
                                                                                                                                                  
  Size                                                                                                                                            
   \< 5 cm               550          463 (123-3242)       0.012       10.58      5.15 (1.02-76.79)     0.129     1.32       1.15 (0.00-18.40)    0.739
   ≥ 5 cm                655          577 (126-2001)                   12.28      7.15 (1.25-139.17)              0.84       0.25 (0.01-8.41)     
                                                                                                                                                  
  Stage                                                                                                                                           
   Stage I               547          471 (123-1586)       0.320       17.60      5.52 (1.02-94.11)     0.907     0.88       0.16 (0.01-6.22)     0.681
   Stage II              711          573 (126-3242)                   10.94      10.94 (1.58-93.08)              1.13       0.28 (0.01-10.09)    
   Stage III             553          495 (139-1620)                   15.67      5.97 (1.25-139.47)              1.07       0.13 (0.00-18.40)    
                                                                                                                                                  
  Differentiation                                                                                                                                 
   Well                  644          495 (123-3242)       0.234       12.07      5.49 (1.02-94.11)     0.275     0.75       0.25 (0.01-6.97)     0.957
   Moderate              541          511 (133-1620)                   18.07      7.45 (1.49-139.17)              1.60       0.15 (0.00-18.40)    
   Poor                  531          520 (174-1083)                   7.45       8.42 (2.65-11.88)               0.28       0.20 (0.00-0.54)     
   Mucinous              805          663 (448-1258)                   13.35      8.30 (1.25-39.03)               0.52       0.18 (0.02-1.60)     

The relationship between serum levels of VEGF, IL-6, CRP, and clinicopahologic variables was evaluated using the Kaplan-Meier method. We established the cutoff value for VEGF (825 pg/mL), IL-6 (8.09 pg/mL), and CRP (0.51 mg/dL) by ROC curve. Univariate log-rank analysis showed that CEA (*p*\< 0.001), regional lymph nodes status (*p*\< 0.001), tumor size (*p*= 0.029), and lymph node ratio (*p*= 0.001) were reduced overall survival. We noted that high VEGF levels tended to reduce overall survival (*p*= 0.053, Figure [1](#F1){ref-type="fig"}), but not significantly. VEGF levels demonstrated no significance with regard to disease free survival (*p*= 0.236, Figure [2](#F2){ref-type="fig"}). IL-6 and CRP levels provided no significant evidence with regard to overall patient survival (*p*= 0.956, *p*= 0.607 respectively) and disease free survival (*p*= 0.531, *p*= 0.701, respectively). Multivariate regression analysis using Cox\'s proportional hazards model revealed that VEGF (*p*= 0.032, HR = 4.779), CEA (*p*= 0.012, HR = 7.981), regional lymph nodes status (*p*\< 0.001), and age (p = 0.005, HR 11.91) were independent prognostic factors for survival of colorectal cancer (Table [4](#T4){ref-type="table"}).

![**Overall survival curve according to VEGF level**.](1471-2407-10-203-1){#F1}

![**Disease free survival curve according to VEGF level**.](1471-2407-10-203-2){#F2}

###### 

Multivariate analysis on OS and DFS in 143 colorectal cancer patients

                                     DFS     OS                                          
  ---------------------------------- ------- ------------ --------- ------- ------------ -------
  VEGF, \<825 vs. ≥825 pg/mL\*       1.281   0.41-4.03    0.672     4.779   1.15-19.94   0.032
  IL-6, \<11.68 vs. ≥11.68 pg/mL\*   1.284   0.44-3.73    0.646     1.391   0.36-5.44    0.634
  CRP, \<0.18 vs. ≥0.18 mg/dL\*      1.030   0.38-2.80    0.954     0.869   0.22-3.51    0.844
  CEA, \<5 vs. ≥5 ng/mL              8.391   2.51-28.07   0.001     7.981   1.44-44.10   0.012
  Tumor size, \<5 vs. ≥5 cm          0.210   0.06-0.81    0.023     3.448   0.29-41.06   0.327
  T, T1 vs. T2 vs. T3 vs. T4         2.479   0.94-6.57    0.068     5.963   0.76-46.87   0.090
  N, N0 vs. N1 vs. N2                4.807   2.38-9.72    \<0.001   5.867   2.86-86.20   0.002
  Stage, I vs. II vs. III            0.783   0.12-5.10    0.798     0.042   0.00-0.67    0.025
  Age, \<60 vs. ≥60                  0.726   0.20-2.59    0.622     11.91   2.14-66.33   0.005

\* cutoff value by ROC curve

Discussion
==========

Recent studies have shown the correlation between tissue VEGF expression and tumor aggressiveness in colon carcinoma. VEGF expression was found to be higher in patients who had metastatic tumors compared with patients who had non-metastatic tumors \[[@B10]\], \[[@B19],[@B20]\]. Takahashi et al \[[@B21]\] showed that VEGF expression level in patients with lymph node negative colon carcinoma was significantly associated with time of recurrence, whereas Cascinu et al \[[@B22]\] confirmed that positive VEGF status was associated with a significant reduction in 5-year DFS rate.

The prognostic impact of serum VEGF levels in cancer patients has been evaluated in a few studies. A large study by [Danish Colorectal Cancer Study Group]{.ul} found that high preoperative VEFG concentrations were associated with reduced overall survival with respect to patients with colon carcinoma who had lower VEGF serum values, and suggested a biologically relevant role for serum VEGF concentration in patients with colorectal carcinoma \[[@B23]-[@B25]\].

According to findings from recent studies, VEGF has been proposed as a potential biomarker for prediction of colorectal cancer prognosis. De Vita et al \[[@B26]\] determined preoperative and post operative serum VEGF levels by ELISA in patients with colon cancer who underwent surgery. They found that preoperative VEGF was significantly higher in the colon cancer compared with the control group, and preoperative VEGF was significantly lower in patients who underwent curative surgery compared with patients who underwent non-curative surgery. Therefore, they suggested that preoperative serum VEGF levels might be useful for prediction of outcome in patients with colon cancer who underwent surgery. Another study investigated VEGF expression in colorectal cancer specimens by performance of immunohistochemistry on tissue microarrays \[[@B27]\]. In that study, the authors found VEGF expression in all tumors evaluated; they also found greater intensity of VEGF staining, greater lymph node metastasis, higher stage, and poorer disease-specific survival. They concluded that VEGF expression in colorectal cancer appears to be an independent prognostic marker of tumor behavior, and that it may be useful in identification of patients with unfavorable clinical outcome.

In our study, preoperative serum VEGF level by ELISA in the patient group was significantly higher than levels in the control group (*p*\< 0.001) and preoperative serum VEGF levels were significantly correlated with CEA levels (*p*= 0.038) and tumor size (*p*= 0.012). When we established the cutoff value for VEGF (825 pg/mL) by ROC curve, we noted that high VEGF levels tended to reduce overall survival, but was not significantly (*p*= 0.053). No significant correlation was found between VEGF preoperative levels and disease stage, gender, tumor depth, and status of lymph node metastasis.

Currently, ample literature is available with regard to the role of various cytokines in colorectal cancer patients. Mechanisms leading to IL-6 induction and to IL-6 presence in high concentrations in the serum of those patients include CEA-induced IL-6 production by Kupffer cells, malignancy-related chronic stress leading to increased IL-6 blood concentrations, as well as direct IL-6 production and secretion by tumor-associated macrophages or the tumor cells themselves. According to some studies that evaluated clinical significance of IL-6 pre-treatment levels, IL-6 concentrations reflected disease status, and were commonly associated with metastatic disease \[[@B28],[@B29]\]. Findings from other research did not reveal a significant association between IL-6 and tumor stage, or other clinical findings \[[@B30]\]. However, the authors of that study found significant correlation between large tumor size and hepatic metastasis correlated with elevated IL-6 levels significantly. Furthermore, high IL-6 levels were associated with reduced overall survival. Different from prior studies, was the fact that it was comprised more of non-metastatic stages, which strengthens the clinical relevance of this observation. They suggested that in the absence of advanced metastatic disease, IL-6 levels may be used as an adverse prognostic marker.

CRP is synthesized in hepatocytes and produced by other organs in response to release of IL-6 by monocytes and other immune cells \[[@B31]\]. Increased CRP level has been previously reported in patients with impaired T lymphocyte response; thus this mechanism is considered to have an association with the immune system and poor survival rate \[[@B32]\]. Elevated levels of this marker of infection have been associated with increased risk of cardiovascular disease \[[@B33]\], and have been identified as a poor prognostic factor for several diseases, including a variety of cancers in a number of previous studies \[[@B34]-[@B37]\]. Findings from studies in patients with colorectal cancer have indicated that those with elevated serum CRP concentrations had poorer prognoses than those whose CRP level did not increase. In addition, it has been suggested that increased CRP was associated with more frequent local tumor invasion \[[@B38]\], more advanced pathologic stage \[[@B39]\], a higher rate of recurrence \[[@B40]\], and reduced overall survival \[[@B30]\].

Unlike results from earlier studies, we were unable to determine the correlation between IL-6 and CRP and prognostic factors. Although IL-6 and CRP levels showed no correlation with other pathological findings, mean and median levels of CRP in colorectal cancer patients were significantly higher than those in normal individuals (*p*= 0.001). When we established the cutoff value for IL-6 (11.68 pg/mL), and CRP (0.185 mg/dL) by ROC curve, IL-6 and CRP showed no significant evidence with regard to disease free survival (*p*= 0.701, *p*= 0.531, respectively) and overall survival (*p*= 0.563, *p*= 0.572, respectively).

This retrospective study had some limitations. First, the patient group was restricted to patients who underwent surgery. Thus this study included more patients who were able to undergo surgery at a lower stage (not included stage IV). And we did not consider patients who underwent surgery or those who had any concomitant disease suspected of raising VEGF, IL-6, or CRP (i.e., chronic inflammatory disorders, diabetes mellitus, ischemic heart disease, etc.). Thus, these were possible causes for misinterpretation of results. The most important limitation of this study is the lack of post operative VEGF, IL-6 and CRP levels. De Vita et al.\[[@B26]\] suggested preoperative VEGF and CEA levels as good prognostic indicators for curative and noncurative surgery, and VEGF levels dropped significantly after surgery, with a further downward trend until the 30th postoperative day. However if we had determined postoperative serum levels of VEGF, IL-6, and CRP, we would have been able to obtain more information with regard to prognosis. For examples, normalization of postoperative serum levels could suggest radical surgery; serum level decrement would show secretion of the marker by the tumor, and patients undergoing potentially curative surgery who does not show serum level normalization of the marker should undergo treatment with chemotherapy regardless of the TNM stage, and increased serum levels during the follow-up period could be prediction of recurrence.

Conclusively, high preoperative VEGF levels were associated with tumor size, higher CEA, and VEGF was independent of overall survival with CEA and lymph node status. Thus we surmise that the prognosis in colorectal cancer patients with high VEGF levels would be generally poor.

Conclusions
===========

As a result of the current study, VEGF is suggested as an important prognostic factor for colorectal cancer. For the future, more prospective studies will be necessary for investigation of predictive biomarkers for colorectal cancer.
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